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A metabolomics study of 
Qiliqiangxin in a rat model of heart 
failure: a reverse pharmacology 
approach
Junzeng Fu1, Liping Chang2,3, Amy C. Harms  1,4, Zhenhua Jia3, Hongtao Wang5, Cong Wei6, 
Li Qiao6, Shuyan Tian2,3, Thomas Hankemeier1,4, Yiling Wu2,3 & Mei Wang7,8
The Chinese medicine Qiliqiangxin (QL) has been shown to have a protective role in heart failure. Here, 
we explore the underlying working mechanism of the key therapeutic component in QL using a rat 
model of heart failure. Heart failure after myocardial infarction was induced surgically and confirmed 
using echocardiography; a separate group of rats underwent sham surgery. The rats with heart failure 
were randomly assigned to receive QL, the angiotensin-converting enzyme inhibitor benazepril, or 
placebo groups. Blood samples were collected from the rats at four time points for up to 8 weeks and 
used for biochemical analysis and mass spectrometry‒based metabolomics profiling. In total, we 
measured nine well-known biochemical parameters of heart failure and 147 metabolites. In the rats 
with heart failure, QL significantly improved these biochemical parameters and metabolomics profiles, 
significantly increasing the cardioprotective parameter angiopoietin-like 4 and significantly lowering 
inflammation-related oxylipins and lysophosphatidic acids compared to benazepril. Mechanistically, 
QL may improve outcome in heart failure by controlling inflammatory process and cardiac hypertrophy. 
Clinical studies should be designed in order to investigate these putative mechanisms in patients.
Heart failure is a complicated clinical syndrome that can result from any functional and/or structural cardiac 
disorder that impairs the ventricle’s ability to fill with or eject blood1. Heart failure is currently one of the leading 
causes of morbidity and mortality worldwide, placing a significant burden on patients, their families, and society2.
In recent decades, Western pharmaceutical-based therapies have shown promising effects in terms of improv-
ing symptoms and reducing heart failure‒related mortality by targeting pathogenic pathways; these therapies 
include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and aldosterone antagonists3. However, 
these treatments are often associated with side effects, including electrolyte imbalance, fluid depletion, and hypo-
tension4. In contrast to the reductionist, molecular target approach of Western medicine, Chinese medicine uses 
a holistic and personalized approach to both diagnosis and intervention of disease, as well as supporting health, 
with fewer side effects and lower costs compared to Western medicine4. Recently, using a systems approach to 
bridge Western and Chinese medicine at the biochemical level has yielded insight into the mechanisms that 
underlie the beneficial effects of Chinese medicines5–7, suggesting that Chinese medicine may provide a comple-
mentary therapy in patients with heart failure.
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Qiliqiangxin (QL) is a well-known herbal medicine derived from a classic traditional Chinese formula. QL 
capsules contain herbal extract from the following herbs: ginseng radix et rhizoma, astragali radix, aconm lateralis 
radix praeparaia, descurainiae semen lepidii semen, salviae miltiorrhizae radix et rhizoma, alismatis rhizoma, cin-
namomi ramulus, polygonati odorati rhizoma, periplocae cortex, carthami flos, and citri reticulatae pericarpium8. 
In China, QL has been used in clinical practice for treating heart failure for more than a decade. In addition, a 
multicenter randomized double-blind study showed that QL has cardioprotective benefits in patients with heart 
failure9. Finally, QL has been reported to reduce cardiac remodeling following acute myocardial infarction in 
mice8. Although these previous studies demonstrated the beneficial effects of QL, the underlying therapeutic 
effects and the underlying mechanisms in the context of heart failure remain poorly understood.
Heart failure is associated with a complex range of pathologies, including profound changes in cardiac metab-
olism10. Thus, several products of multiple cardiac metabolic pathways, including metabolites related to inflam-
mation and energy metabolism, are important intermediates in the pathogenesis of heart failure10–12. Here, we 
used biochemical assays to measure several parameters that are commonly used as markers in heart failure‒
related research. In addition, we used mass spectrometry‒based metabolomics profiling to measure a wide range 
of metabolites, including oxylipins, oxidative and nitrosative stress markers, and organic acids. Finally, we used 
these biochemical parameters and metabolomics profiles to systematically examine the molecular mechanisms 
that underlie heart failure and therapeutic interventions.
For this study, we investigated the effect of QL treatment for up to 8 weeks in rats with heart failure, and we 
compared its effect with the Western drug benazepril. We found that QL has a significant beneficial effect in the 
treatment of heart failure in terms of improving the levels of markers of heart failure. Compared to benazepril, QL 
provides unique therapeutic benefits with respect to regulating metabolites related to inflammation and cardiac 
hypertrophy in heart failure.
Methods
Animal model and study design. This study was approved by the ethics committee of the Integrated 
Traditional Chinese and Western Medicine Research Institute of Hebei Province, and all animal experiments were 
conducted in accordance with the “Guide for the Care and Use of Laboratory Animals” published by the National 
Institutes of Health (No. 85–23, revised 1996).
Rat model of heart failure after acute myocardial infarction. Male Sprague-Dawley rats weighing 200–220 g were 
purchased from Huafukang Biological Technology Co., Ltd. (Beijing, China) and housed in group cages at 22 °C 
with a 12 h light/12 h dark cycle for three days with ad libitum access to standard chow and water. The rats were 
randomly assigned to undergo either acute myocardial infarction (AMI) surgery or sham surgery. AMI surgical 
model was induced by ligation of the left anterior descending. Five weeks after ligation, echocardiography was 
performed, and rats with left ventricular ejection fraction ≤45% were diagnosed as having heart failure (n = 120 
rats). The rats in the sham surgery group were treated exactly the same as the AMI group, except the artery was 
not ligated (n = 48 rats).
Interventions. Starting on day 1 following surgery, the rats were treated with QL (1 g/kg/day), benazepril (10 mg/
kg/day), or physiological saline solution (PSS), administered by oral gavage. QL is the medicinal powder of 
Qiliqiangxin capsules, which was provided by Shijiazhuang Yiling Pharmaceutical (Shijiazhuang, Hebei, China). 
The material was produced by a verified process and contains consistent concentrations of herbal constituents8. 
Benazepril was used as a positive control for intervention and was purchased from Beijing Novartis Pharma Co., 
Ltd. (Beijing, China; batch number X2137). PSS was used as a negative control.
Animal groups and study design. The rats were assigned to their respective groups on day 0. The rats in the sham 
surgery group were randomized into the following four groups: one group was sacrificed immediately after ran-
domization (day 0), and the other three groups received PSS and were sacrificed on day 28, day 42, or day 56 (see 
Fig. 1). The rats with heart failure were randomized into the following ten groups: one group was sacrificed after 
randomization; the other nine groups were divided into intervention type (QL, benazepril, or PSS) and sacrifice 
day (day 28, day 42, or day 56). On the indicated days, plasma samples were collected in lithium heparin tubes 
and immediately centrifuged at 1050 × g for 10 min at 4 °C; 500-µl aliquots were stored at −80 °C and used for the 
following measurements.
Biochemical analysis. Biochemical parameters which were clinically relevant to heart failure were meas-
ured in all plasma samples. Angiopoietin-like 4 (AngPTL-4), neuregulin-1 (NRG-1), 3-nitrotyrosine (3-NT), 
arginine vasopressin (AVP), and calcitonin gene-related peptide (CGRP) were each measured using the respec-
tive ELISA. Renin (RI), angiotensin II (AII), aldosterone (ALD) were measured by using a radioimmunoassay kit, 
and free fatty acids (FFAs) were measured using an FFA kit.
Metabolomics profiling. Plasma samples were measured using organic acids, oxidative stress, and oxylipins 
platforms in order to cover a wide spectrum in the metabolomics profile. From each sample, 50, 100, and 150 µl 
samples of plasma were prepared using the TECAN EVO Freeware (Männedorf, Swaziland). The stability of the 
platforms used was monitored using quality control (QC) samples and duplicate samples. A QC pool was made 
from study samples and used for QC and batch correction for all platforms. These QC samples were measured 
after every 10 samples. In addition, 15% of samples were run as duplicate samples for each platform (where sam-
ple volume allowed).
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All analyses were performed by the Biomedical Metabolomics Facility Leiden at Leiden University using 
standard operating procedures based on previously published methods13–15. Details regarding these methods are 
provided in the Supplementary Methods, and the target metabolites are listed in Supplementary Tables S1-S3.
Organic acids. The organic acid platform uses untargeted gas chromatography-mass spectrometry com-
bined with a target list of well-characterized metabolites for the analysis of organic acids, fatty acids, sugars, 
amines, and primary metabolites in complex biological matrices. The method uses a combination of an oxima-
tion reaction using methoxyamine hydrochloride and a silylation reaction using N-methyl-N-(trimethylsilyl)
trifluoroacetamide13.
Oxylipins. The oxylipin platform uses a complete targeted liquid chromatography-tandem mass spectrometry 
approach with a defined target compound list covering the classic and non-classic eicosanoids derived from var-
ious polyunsaturated fatty acids (PUFAs), including n-6 and n-3 PUFAs such as linoleic acid, arachidonic acid, 
eicosapentaenoic acid, and docosahexaenoic acid14.
Oxidative stress‒related metabolites. The oxidative stress platform uses LC-MS/MS and covers various isopros-
tane classes together with their respective prostaglandin isomers derived from different PUFAs, including n-6 
and n-3 PUFAs such as dihomo-γ-linoleic acid, arachidonic acid, and eicosapentaenoic acid. This platform also 
includes signaling lipids from the sphingosine and sphinganine classes, and their phosphorylated forms, as well 
as three classes of lysophosphatidic acids. The three lysophosphatidic acid classes include lysophosphatidic acids 
(LPAs), alkyl-lysophosphatidic acids (aLPAs), and cyclic-lysophosphatidic acids (cLPAs), all of which range from 
C14 to C22 chain length species15.
Data preprocessing. The raw organic acid and oxylipin data were preprocessed using Agilent MassHunter 
Quantitative Analysis software (version B.05.01; Agilent Technologies, Santa Clara, CA). The oxylipin response 
was quantified using the peak area ratios between the target analyte and the respective internal standard. The 
raw oxidative stress data were evaluated using LabSolutions software (version 5.72; Shimadzu, Kyoto, Japan) by 
integrating the assigned multiple reaction monitoring peaks and normalizing each peak to the respective internal 
standard. Where available, a deuterated version of the target compound was used as an internal standard; other-
wise, the closest-eluting internal standard was used.
For each platform, we first used performed internal standard correction followed by additional corrections 
using the QC samples in order to compensate for possible changes in the sensitivity of the mass spectrometer 
during the measurements. The quality of these corrections was evaluated by examining duplicate samples. Only 
metabolites with a relative standard deviation <0.30 in the duplicate samples and QC samples were used for sub-
sequent analyses. Metabolites with a level below its limit of detection were replaced by 50% of the minimal value 
of the corresponding metabolite.
Statistical analysis. Preprocessed metabolomics data were standardized prior to statistical analysis. Data 
were analyzed using an independent t-test, an one-way ANOVA, or a two-way ANOVA. All analyses were per-
formed using IBM SPSS for Windows (version 24, Armonk, NY).
Data availability. The datasets that were generated and analyzed in this study are available from the corre-
sponding author upon request.
Figure 1. Study design. Be: Benazepril; HF: heart failure group; PSS: physiological saline solution; QL: 
medicinal powder of Qiliqiangxin capsules; Sh: Sham surgery group. Each tube represents a group. This figure 
was drawn by the author J. Fu using the software Adobe Illustrator (version CC 2015.2.0) and the image bank of 
Servier Medical Art. URL to the images are http://smart.servier.com/smart_image/rat/ and http://smart.servier.
com/smart_image/tube-29/. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 
3.0 Unported License. https://creativecommons.org/licenses/by/3.0/.
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Results and Discussion
Time-dependent effects of QL on heart failure. QL improves biochemical parameters in a rat model of 
heart failure. At four time points (see Fig. 1), we measured nine well-known biochemical parameters relevant 
to heart failure in order to investigate the pathophysiological processes that underlie the disease. These nine bio-
chemical parameters were: RI, AII, ALD, CGRP, AVP, FFAs, AngPTL-4, NRG-1, and 3-NT. RI, AII, and ALD play 
key roles in the renin-angiotensin-aldosterone system (RAAS), an important pathway involved in the pathogene-
sis of heart failure; in clinical practice, inhibiting the production of RI, AII and/or ALD can significantly increase 
survival in heart failure16. CGRP is a potent vasodilator, and increased CGRP levels in patients with appear to 
be correlated with disease severity17. AVP is an endogenous antidiuretic hormone, and increased levels can lead 
to an inappropriate retention of water in the body and constrict blood vessels in patients with heart failure18. 
FFAs play an important role in energy metabolism in the heart, and increased-FFA levels have been reported in 
patients with heart failure19,20. AngPTL-4 is a member of the AngPTL family of proteins and is involved in both 
lipoprotein metabolism and angiogenesis21. NRG-1 is a member of the epidermal growth factor family and has 
been reported to improve cardiac function and has beneficial effects in heart failure22. Finally, 3-NT is a product 
of tyrosine nitration, which is mediated by reactive nitrogen species, and increased levels of NT have been asso-
ciated with systemic inflammation in patients with heart failure23.
Independent t-test and one-way ANOVA with LSD post hoc test were used to analyze the differences 
in biochemical parameters between the various surgery and treatment groups at all four time points (see 
Supplementary Table S4). As shown in Fig. 2, at all four time points, all nine biochemical parameters differed 
significantly between the placebo-treated heart failure (HF + PSS) and sham (Sh + PSS) groups. In the rats with 
heart failure, both interventions (i.e., QL and benazepril) significantly reversed all nine parameters compared 
to the HF + PSS group. Moreover, the effect of QL on AngPRL-4 was stronger than benazepril at all three time 
points, whereas CGRP and NRG-1 differed significantly between the two intervention groups only on day 56. 
Compared to the sham group, AngPLT-4 levels were higher in the HF + QL group, but not in the HF + Be group 
(see Supplementary Table S5). Thus, QL may have be more potent than benazepril in stimulating the production 
of AngPLT-4 in order to compensate for the damage caused by heart failure, resulting in higher levels than in the 
sham surgery group. This suggests that QL may have additional effects in terms of regulating AngPTL-4 related 
pathways in rats with heart failure, thus improving cardiac function by regulating lipoprotein metabolism and 
angiogenesis.
Figure 2. Biochemical parameters measured in the plasma of rats in the sham surgery/placebo-treated 
(Sh + PSS) and heart failure/placebo-treated (HF + PSS), heart failure/QL-treated (HF + QL), and heart 
failure/benazepril-treated (HF + Be) groups in day 0, day 28, day 42, and day 56. Values are presented as the 
mean ± SD. a: versus Sh + PSS; b: versus HF + PSS; c: versus HF + QL. *p < 0.05, **p < 0.01, ***p < 0.001.
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QL affects potential metabolic markers for heart failure. Potential metabolic markers for heart failure: In total, 
147 metabolites were measured, including 25 organic acids, 71 oxylipins, and 51 oxidative stress metabolites. 
These data were first normalized by converting each measurement to a Z score using the formula [(X-X)/SD], 
where X  is the value obtained for a given metabolite in one sample, X is the mean value of that metabolite in all 
samples, and SD is the standard deviation of the metabolite in all samples. Next, a two-way ANOVA was used to 
determine which metabolites differed significantly between the heart failure and sham rats. A total of 41 metabo-
lites differed significantly between the HF + PSS and Sh + PSS groups and are shown in Fig. 3, which shows the 
mean Z scores for each metabolite in each group, with each cell colored to indicate the magnitude of the mean Z 
score.
A total of 6 organic acids, 4 cLPAs, aLPA (C16:1), platelet-activating factor (PAF C16:0), oxidative stress 
marker 13,14-dihydro-PGF2a, and sphingosine C18:1 were significantly lower in the HF + PSS group compared 
to the Sh + PSS group; in contrast, 15 oxylipins, 11 LPAs, and the nitrosative stress marker NO2-LA were sig-
nificantly higher in the HF + PSS group. The metabolites 17,18-DiHETE, 19,20-DiHDPA, 5,6-DiHETrE, and 
9,10-DiHOME have been reported to have a positive correlation with mortality among patients in systolic heart 
failure who received an implantable cardioverter defibrillator a primary prevention24. The enzymes and path-
ways involved in LPA metabolism and signaling play a role in atherosclerosis, as well as in experimental models 
of cardiovascular disease25. Sphingosine can be phosphorylated to produce sphingosine-1-phosphate, a potent 
signaling lipid involved in the pathogenesis of heart failure24. Nitrosative stress and oxidative stress have also 
been implicated in the pathogenesis of heart failure26. Importantly, our results provide the first evidence that 
downstream products of nitrosative and oxidative stress (NO2-LA and 13,14-dihydro-PGF2a) play a role in a rat 
model of heart failure. Our results also provide the first evidence that methylmalonic acid, pyroglutamic acid, 
aspartic acid, and 3-hydroxyisovaleric acid are associated with heart failure. The remaining metabolites identified 
in our study have been previously reported to be associated—either directly or indirectly—with heart failure27–30. 
Therefore, the metabolites identified in our analysis may play a key role in the pathogenesis of heart failure, and 
they may be useful as novel metabolic markers for disease progression in heart failure and/or targets for improv-
ing treatment outcome.
The effects of QL and benazepril on potential metabolic markers: Next, we examined the effects of treat-
ing heart failure rats with QL and benazepril with respect to these potential metabolic markers using a two-way 
ANOVA, with the intervention considered as one factor. Our analysis revealed that QL and benazepril signifi-
cantly affected 21 and 16 metabolites (see Table 1), respectively; nine metabolites were affected by both inter-
ventions QL significant reduced 11 out of the 15 oxylipins, whereas benazepril significantly decreased only 5 
oxylipins. In addition, QL significantly decreased all 11 LPAs, whereas benazepril decreased only 4 LPAs. The lev-
els of each metabolite in each group are shown in Supplementary Fig. S1. Taken together, these results suggest that 
QL may be more effective than benazepril at regulating oxylipin and LPA metabolism in rats with heart failure.
QL treatment had no significant effect on organic acid levels, whereas benazepril increased both pyroglu-
tamic acid and aspartic acid. Aspartic acid is widely used to reduce cardiac ischemia/reperfusion during cardiac 
Figure 3. Summary of the 41 metabolites that differed significantly between the sham/placebo-treated group 
(Sh + PSS) and the heart failure/placebo-treated group (HF + PSS) at the indicated time points. Each number 
represents the mean standardized value (Z score) for each metabolite in the indicated group, and the color of 
each cell indicates the magnitude and direction of each Z score.
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surgery31. Thus, the increased in aspartic acid may explain the potentially cardioprotective effect of benazepril. 
In other hand, high levels of aspartic acid may have toxic effects on the kidneys and salivary glands in rats32. 
Therefore, further study is needed in order to investigate more thoroughly the putative relationship between 
benazepril-induced changes in aspartic acid and cardioprotection.
Regulation of heart failure‒related pathways by QL: a possible working mechanism. Studying 
a drug’s mechanism of action is one of the most important tasks in drug research. Because Qiliqiangxin Capsules 
showed positive clinical effects in the treatment of heart failure, we used a reverse pharmacology approach to 
investigate the underlying mechanism. Specifically, we used metabolomics profiling and biochemical assessment 
to explore the possible molecular targets of QL, using benazepril as a positive control.
Pathway analysis. To investigate the working mechanism of QL, the related biochemical parameters and 
metabolites are summarized in Fig. 4 using pathways reported in the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) database, the published literature, and the Boehringer metabolic chart33.
Heart failure, a complex condition involving pathological perturbation in a variety cardiac metabolic systems, 
has been linked to inflammation23. Oxylipins are potent inflammatory markers that have been associated with 
responses to cardiovascular disease, host defense, tissue injury, and surgical intervention14. In vivo, oxylipins 
are present as oxygenated 20-carbon lipids derived from PUFAs via enzymatic (e.g., COX, CYP450, or LOX) 
or non-enzymatic oxidative or nitrosative (e.g., RNS) reactions (see Fig. 4.). Here, we found that rats with heart 
failure had significantly higher levels of 15 oxylipins compared to rats in the sham surgery group, indicating that 
heart failure evokes an inflammatory response. As discussed above (see section ‘The effects of QL and benazepril 
on potential metabolic markers’), treating rats in the heart failure group with QL reduced 11 of these 15 oxylipins, 
compared to only five oxylipins reduced by benazepril treatment. These results indicate that QL is more effective 
than benazepril at modulating inflammation due to heart failure.
Metabolite
p-value
HF + PSS vs. HF + QL HF + PSS vs. HF + Be
Pyroglutamic acid 0.129 0.004 ↑
Aspartic acid 0.140 0.011 ↑
9,10,13-TriHOME 0.045 ↓ 0.087
12,13-DiHODE 0.002 ↓ 0.009 ↓
9,10-DiHOME 0.030 ↓ 0.392
9-HOTrE 0.002 ↓ 0.002 ↓
5,6-DiHETrE 3.24E-05 ↓ 0.277
12,13-EpOME 0.011 ↓ 0.073
9,10-EpOME 4.34E-04 ↓ 2.408E-04 ↓
9-KODE 2.02E-05 ↓ 0.001 ↓
13-KODE 1.11E-07 ↓ 0.004 ↓
16,17-EpDPE 0.027 ↓ 0.226
LPA-C14:0 0.006 ↓ 0.107
LPA-C16:0 0.040 ↓ 0.081
LPA-C16:1 0.013 ↓ 0.711
LPA-C18:1 0.003 ↓ 0.106
LPA-C18:2 4.45E-06 ↓ 7.141E-05 ↓
LPA-C18:3-ω3ω6 0.017 ↓ 0.441
LPA-C20:3 0.001 ↓ 0.081
LPA-C20:4 0.007 ↓ 0.003 ↓
LPA-C20:5 1.81E-04 ↓ 0.812
LPA-C22:5 2.26E-04 ↓ 0.005 ↓
LPA-C22:6 0.003 ↓ 1.084E-04 ↓
PAF-C16:0 0.553 0.001 ↑
cLPA-C16:0 0.391 0.020 ↑
cLPA-C18:1 0.251 0.036 ↑
aLPA-C16:1 0.216 0.029 ↑
NO2-LA 0.839 0.024 ↓
Table 1. Summary of the effects of QL and benazepril on potential metabolic markers in rats with heart failure 
Notes: p-values shown in bold indicate p < 0.05; HF, heart failure; PSS, physiological saline solution ↓: Lower 
levels in the QL- or benazepril-treated groups (HF + QL or HF + Be) compared to the placebo-treated group 
(HF + PSS); ↑: Higher levels in the QL- or benazepril-treated groups (HF + QL or HF + Be) compared to the 
placebo-treated group (HF + PSS).
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In the untreated rats with heart failure (i.e., the HF + PSS group), 11 LPAs were significantly increased, and 4 
cLPAs were significantly decreased. LPAs are growth factor‒like phospholipid mediators, and one of the major 
pathways for their production is via the hydrolysis of lysophosphatidylcholine (LPC) by lysophospholipase D34. 
Cyclic analogs of LPAs (cLPAs) are also generated from lysophosphatidylcholine by an enzyme that shares several 
peptide fragments with lysophospholipase D27. Therefore, LPAs and cLPAs are produced from lysophosphatidyl-
cholines via the activity of two similar phospholipases. QL treatment significantly decreased all LPAs; in contrast, 
benazepril treatment reduced only four LPAs and increased two cLPAs. These results suggest that both QL and 
benazepril exert effects on the LPA/cLPA-related pathways. Thus, QL may have a stronger effect in terms of inhib-
iting LPA generation, whereas benazepril may only modestly inhibit LPA generation while stimulating the pro-
duction cLPAs. LPAs have important functions in extracellular signaling, including inducing platelet aggregation 
and vascular smooth muscle cell contraction, increasing arterial blood pressure, and promoting angiogenesis in 
rats25,34,35. Angiogenesis is closely correlated with cardiac hypertrophy, which is an adaptive response to physio-
logical and pathological overload36. Initially, this response is functional, compensatory, and adaptive; however, 
when sustained, the response can lead to structural changes that become self-perpetuating and pathogenic37. In 
contrast, cLPAs have unique functions such as inhibiting LPA-induced platelet aggregation38. Therefore, QL may 
improve cardiac hypertrophy by decreasing LPA levels, thereby contributing to recovery from heart failure over 
the long term.
In the healthy mammalian heart, the majority of energy is produced from the β-oxidation of fatty acids; in 
heart failure, oxidation of myocardial fatty acids is reduced10,39. This finding may partially explain our finding of 
increased levels of FFAs in rats with heart failure. Importantly, FFA levels were significantly decreased in rats that 
were treated with QL or benazepril, suggesting that both interventions increase myocardial fatty acid oxidation in 
order to normalize FFA levels in heart failure. In placebo-treated rats with heart failure (i.e. HF + PSS group), sev-
eral organic acid levels were decreased compared to rats in the sham surgery group (i.e. Sh + PSS group), which 
may indicate the changes in the tricarboxylic acid (TCA) cycle, as well as in the valine, leucine, and isoleucine 
degradation pathways. Valine, leucine, and isoleucine are branched-chain amino acids (BCAAs)33 and BCAAs 
may provide an alternative source of energy for maintaining heart function40. Thus, decreased levels of organic 
acids in rats with heart failure may suggest a perturbation in energy production in this group. In our study, QL 
had no significant effect terms of modulating these organic acids, whereas benazepril significantly increase two 
organic acids related to the TCA cycle (pyruvic acid and aspartic acid).
Comparison between QL and benazepril treatment in rats with heart failure. In this study, we used benazepril 
and PSS as a positive and negative control, respectively, for intervention in rats with heart failure. Benazepril is an 
ACE inhibitor that is used to treat heart failure by acting on the RAAS, thereby driving sodium and water reten-
tion and lowering blood pressure.
Both QL and benazepril significantly improved a number of disease-related biochemical parameters in rats 
with heart failure, including RI, AII, ALD, AVP, 3-NT, FFA, and CGRP, suggesting that their therapeutic effects 
are mediated by inhibiting RAAS, reducing water retention, decreasing reactive nitrogen species (RNS)-induced 
inflammation, and promoting the oxidation of myocardial fatty acids. Only three biochemical parameters—
namely, AngPTL-4, CGRP and NRG-1—were affected differently between QL and benazepril treatment. In par-
ticular, AngPTL-4 levels were consistently higher in the QL-treated group compared with the benazepril-treated 
group (p < 0.001). AngPTL-4 is an inhibitor of lipoprotein lipase; thus increased levels of AngPTL-4 can reduce 
the production of lipoprotein-derived fatty acids, thereby stimulating lipolysis and fatty acid oxidation41. This 
Figure 4. Pathway analysis of metabolites that are increased or decreased in rats with heart failure, and the 
effect of treatment with QL or benazepril. AA: arachidonic acid; Be: benazepril; COX: cyclooxygenase; CYP450: 
cytochrome P450; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FFA: free fatty acid; HF: heart 
failure; LA: linoleic acid; LOX: lipoxygenase; RNS: reactive nitrogen species; TCA: tricarboxylic acid.
www.nature.com/scientificreports/
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finding suggests that QL may be more effective than benazepril at restoring lipid metabolism in heart failure. With 
respect to metabolomics pathways, QL was more effective than benazepril at controlling LPA and oxylipin levels. 
This suggests that QL may have unique therapeutic benefits with respect to controlling cardiac hypertrophy and 
inflammation associated with heart failure, thereby improving long-term outcome.
Benazepril is relatively safe and effective for treating patients with heart failure42. Although Qiliqiangxin 
Capsule is derived from a traditional Chinese medicine formula and has been used successfully in clinical prac-
tice, it is a relatively new medicine compared to benazepril. Therefore, the above-mentioned effects of QL on bio-
chemical and metabolic markers may contribute to our understanding of its functional mechanisms in treating 
heart failure.
Conclusions
In this study, we used targeted metabolomics profiling and biochemical assessment in plasma samples obtained 
from rats with heart failure treated under various conditions. In rats with heart failure, nine biochemical param-
eters and 41 metabolites differed significantly compared to rats in the sham surgery group. All of the biochemi-
cal parameters and metabolites identified in our study can be measured in plasma samples obtained from both 
humans and rats, and these markers should be examined further in studies involving patients with heart failure. 
QL significantly improved several clinically relevant biochemical parameters. Compared to benazepril, QL led 
to significantly higher levels of AngPLT-4, as well as lower levels of oxylipins and LPAs. These results suggest that 
QL may be therapeutically beneficial in terms of controlling cardiac hypertrophy and inflammation, as well as 
promoting lipid metabolism in heart failure, thereby providing a novel mechanism for promoting recovery in 
these patients.
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